PR – Aanastra

PRESS RELEASES AND PUBLICATIONS

Aanastra Inc Announces Presentations of Preclinical Data at Upcoming Conferences in Support of its Lead Programs for Anti-CD19 In Vivo CAR-T (AAN-14x) and In vivo Rescue of P53 Mutations in Tumors (AAN-53x)

October 14, 2025

Aanastra Inc presents preclinical data on its p53 tumor suppressor rescue and its in vivo anti-CD19 CART programs at the ASGCT Annual Meeting, New Orleans

May 13-17, 2025

Aanastra Inc to highlight its technology in Multiple Presentations at the Advancing Gene and Cell Therapies for Cancer Conference, Philadelphia

October 15-16, 2025

Aanastra Inc presents preclinical data on its in vivo anti-CD19 CART program at the AACR Annual Meeting, Chicago

April 25-30, 2025

Aanastra Inc and Divincell SAS present a “Peptide-based nanoparticle platform for extrahepatic targeted delivery of mRNA and gene editing” at the 4th mRNA Based Therapeutics Summit Europe, Frankfurt

January 28-30, 2025

Aanastra Inc and Divincell SAS present a “A new Peptide nanoparticle platform for extrahepatic targeted delivery of therapeutic mRNAs” and “mRNA delivery for Factor VIII rescue in hemophilia and gene editing of PCSK9 for cholesterol lowering” at the 31st European Society of Gene and Cell Therapy (ESGCT) Annual Congress, Rome

October 22-25, 2024

Aanastra Inc to Showcase its Peptide-RNA Therapeutics Technology in Multiple Presentations at the American Society for Gene and Cell Therapies (ASGCT) Annual Meeting 2024, Baltimore

May 07-11, 2024

Aanastra Inc to Present Multiple Posters on RNA Therapeutics at the American Association for Cancer Research (AACR) Annual Meeting, San Diego

April 05-10, 2024